Solid Dispersion Formulation for CK1α Degrader Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of research on the polymorphism, amorphous form, and formulation of the compound of formula A, a new generation of CK1α selective molecular glue degrader, which is essential for improving stability, solubility, and bioavailability in the development of drugs for treating proliferative disorders.
Innovation Solution
A solid dispersion comprising the compound of formula A or its derivatives, crystalline forms, amorphous forms, or pharmaceutically acceptable salts, combined with carriers such as homopolymers and copolymers, is developed to enhance oral bioavailability and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the compound of formula A is developed as a new generation CK1α selective molecular glue degrader, then the therapeutic effectiveness for treating proliferative disorders is improved, but the lack of research on polymorphism and amorphous form leads to poor stability and solubility
Solution Approach 1:
The patent changes the physical state parameter of the compound from crystalline to amorphous form, and develops solid dispersion formulations with different carriers (polymers, polysaccharides) to optimize stability and solubility while maintaining therapeutic effectiveness
Solution Approach 2:
The patent creates composite solid dispersion systems combining the compound of formula A with various carriers including homopolymers, copolymers, and polysaccharides to improve stability, solubility, and bioavailability while preserving therapeutic activity
2Ease of manufacture
If the compound of formula A is formulated in traditional forms, then the development process is simpler, but the oral bioavailability and peak drug concentration are insufficient
Solution Approach 1:
The patent changes the formulation parameters by developing solid dispersion systems with optimized carrier ratios, particle size, and physical state to enhance oral bioavailability and peak drug concentration while maintaining manufacturability through established solid dispersion preparation methods
3Loss of time
If the compound of formula A is developed without comprehensive screening of crystalline and amorphous forms, then the development time is reduced, but the solubility and bioavailability are compromised
Solution Approach 1:
The patent performs preliminary characterization of the compound in both crystalline and amorphous forms, and pre-establishes solid dispersion formulations with multiple carriers before clinical development, thereby optimizing solubility and bioavailability while managing development time through systematic early-stage screening
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A solid dispersion, a preparation method therefor, and use thereof. The solid dispersion comprises an active ingredient: the compound of formula A or a derivative thereof, a crystal form thereof, an amorphous form thereof, or a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and comprises a carrier. The solid dispersion can significantly improve the oral bioavailability of the active ingredient and has good solid stability, causing the active ingredient to show higher plasma exposure in a rat.